Total Payments
$247,191
2024 Payments
$34,334
Companies
19
Transactions
216
Medicare Patients
877
Medicare Billing
$213,124
Payment Breakdown by Category
Consulting$171,772 (69.5%)
Travel$41,198 (16.7%)
Other$27,938 (11.3%)
Food & Beverage$4,050 (1.6%)
Research$2,210 (0.9%)
Education$23.77 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $171,772 | 60 | 69.5% |
| Travel and Lodging | $41,198 | 72 | 16.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,813 | 10 | 8.0% |
| Honoraria | $8,125 | 4 | 3.3% |
| Food and Beverage | $4,050 | 64 | 1.6% |
| Unspecified | $2,210 | 3 | 0.9% |
| Education | $23.77 | 3 | 0.0% |
Payments by Type
General
$244,981
213 transactions
Research
$2,210
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $88,502 | 66 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $40,856 | 32 | $0 (2023) |
| ARRAY BIOPHARMA INC | $17,497 | 9 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $16,569 | 25 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $12,994 | 18 | $0 (2024) |
| EMD Serono, Inc. | $10,589 | 9 | $0 (2019) |
| GENZYME CORPORATION | $8,817 | 9 | $0 (2018) |
| Incyte Corporation | $8,191 | 8 | $0 (2018) |
| PFIZER INC. | $8,166 | 8 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $8,046 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,334 | 21 | Merck Sharp & Dohme LLC ($20,008) |
| 2023 | $21,921 | 29 | Merck Sharp & Dohme LLC ($7,314) |
| 2022 | $21,293 | 17 | Merck Sharp & Dohme LLC ($11,396) |
| 2021 | $24,923 | 9 | Merck Sharp & Dohme Corporation ($12,011) |
| 2020 | $24,664 | 17 | Novartis Pharmaceuticals Corporation ($8,708) |
| 2019 | $48,637 | 44 | Novartis Pharmaceuticals Corporation ($18,459) |
| 2018 | $48,870 | 57 | Merck Sharp & Dohme Corporation ($18,533) |
| 2017 | $22,548 | 22 | Merck Sharp & Dohme Corporation ($7,501) |
All Payment Transactions
216 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 09/10/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PF06647263 CLINICAL PUBLICATION PROGRAM | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,662.00 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $831.00 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $415.50 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $415.50 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $415.50 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $131.63 | General |
| Category: ONCOLOGY | ||||||
| 06/02/2024 | PFIZER INC. | LORBRENA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 05/06/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $9,760.00 | General |
| 05/06/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 04/19/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $238.06 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $48.69 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $32.46 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $383.07 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $238.06 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $9,157.80 | General |
| Category: ONCOLOGY | ||||||
| 02/29/2024 | Celltrion, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,745.00 | General |
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $359.65 | General |
| 01/03/2024 | PFIZER INC. | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 12/01/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $151.01 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,490.00 | General |
| 11/20/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/09/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $680.24 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| PF06647263 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 238 | 528 | $418,576 | $65,380 |
| 2022 | 2 | 181 | 477 | $381,825 | $60,540 |
| 2021 | 4 | 254 | 420 | $304,740 | $46,316 |
| 2020 | 3 | 204 | 448 | $333,372 | $40,889 |
Total Patients
877
Total Services
1,873
Medicare Billing
$213,124
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 174 | 463 | $358,211 | $56,489 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 45 | 45 | $48,825 | $7,137 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 19 | 20 | $11,540 | $1,754 | 15.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 139 | 435 | $336,255 | $54,249 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 42 | 42 | $45,570 | $6,291 | 13.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 122 | 258 | $199,434 | $32,316 | 16.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 92 | 121 | $69,817 | $8,955 | 12.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $30,380 | $4,495 | 14.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 13 | $5,109 | $550.55 | 10.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 119 | 325 | $251,225 | $30,586 | 12.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 63 | 101 | $58,277 | $6,953 | 11.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 22 | 22 | $23,870 | $3,350 | 14.0% |
About Dr. Adil Daud, MD
Dr. Adil Daud, MD is a Internal Medicine healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699706812.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adil Daud, MD has received a total of $247,191 in payments from pharmaceutical and medical device companies, with $34,334 received in 2024. These payments were reported across 216 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($171,772).
As a Medicare-enrolled provider, Daud has provided services to 877 Medicare beneficiaries, totaling 1,873 services with total Medicare billing of $213,124. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Medical Oncology
- Location Tampa, FL
- Active Since 07/05/2006
- Last Updated 12/28/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1699706812
Products in Payments
- MEKINIST (Drug) $30,132
- BRAFTOVI (Drug) $16,250
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $11,588
- Bavencio (Biological) $10,589
- NO PRODUCT DISCUSSED (Drug) $8,817
- Lenvima (Drug) $7,905
- Zelboraf (Biological) $6,507
- Braftovi (Drug) $5,659
- OPDIVO (Biological) $5,523
- LIBTAYO (Biological) $5,146
- KEYTRUDA (Biological) $4,146
- Parsabiv (Biological) $3,862
- TAFINLAR (Drug) $3,350
- TECENTRIQ (Biological) $2,158
- LENVIMA (Drug) $1,400
- Amtagvi (Drug) $685.00
- IMFINZI (Drug) $660.55
- Tavneos (Drug) $487.50
- PDR001 (Drug) $333.22
- LORBRENA (Drug) $150.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tampa
Javier Pinilla-Ibarz, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Alberto Chiappori, Md, MD
Internal Medicine — Payments: $617,120
Internal Medicine $617,120
Ricardo Restrepo-Jaramillo, M.d, M.D
Internal Medicine — Payments: $562,511
Internal Medicine $562,511
Dr. Sady Alpizar, Md, MD
Internal Medicine — Payments: $509,824
Internal Medicine $509,824
Jhanelle Gray, Md, MD
Internal Medicine — Payments: $273,892
Internal Medicine $273,892
Dr. Andrew Kuykendall, M.d, M.D
Internal Medicine — Payments: $273,357
Internal Medicine $273,357